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doi:10.1016/j.ejvs.2009.12.030Abstract Objectives: Cryoplasty combines conventional angioplasty e percutaneous trans-
luminal angioplasty (PTA) e with cold thermal energy. In this animal study, we investigated
if preventive cryoplasty could reduce intimal hyperplasia (IH) at the venous anastomosis.
Design: We investigated cryoplasty versus PTA of the venous anastomosis in a validated
porcine, bilateral, arteriovenous graft model.
Animals and methods: In 12 pigs, 24 expanded polytetrafluoroethylene (ePTFE) grafts were
bilaterally inserted between the common carotid artery and internal jugular vein. Directly
after surgery, one venous anastomosis was treated with cryoplasty at 10 C, the contralateral
anastomosis with conventional PTA. At 4 weeks, graft flow was measured, quantitative angiog-
raphy was performed and grafts with adjacent vessels were excised for histological analysis.
Results: Due to a number of thromboses, data for paired analysis were available from eight
pigs. Angiographic outflow vein diameter and graft blood flow were not different between
treatment groups. Compared with the control group, IH at the venous anastomosis was
reduced by 47% (PZ 0.21) and intima/media ratio was reduced by 45% (PZ 0.07) by cryo-
plasty. Effects were most profound in those animals that tended to develop most IH.
Conclusion: Our results suggest that preventive cryoplasty of the venous anastomosis might
help to reduce IH in those cases that develop most profound IH.
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1, midazolam 0.4 mg kg1 and atropineArteriovenous vascular access grafts are currently used by
42% of haemodialysis patients in the United States.1 One-
year primary and secondary patency rates of these grafts
are 40% and 60%, respectively.2 Haemodialysis graft failure
is predominantly caused by progressive intimal hyperplasia
(IH) in the venous outflow tract,3,4 which is characterised
by vascular smooth muscle cell proliferation, extracellular
matrix deposition and angiogenesis within the neointima
and adventitia.5,6 According to the current guidelines, pre-
emptive treatment of the stenosis is mandatory to prevent
graft thrombosis.7,8 Percutaneous transluminal angioplasty
(PTA) is the preferred method for graft salvaging.
In search for treatment alternatives, most clinical studies
aimed at secondary IH prevention while a validated animal in
vivo restenosis model is not available. Cryoplasty is a novel
endovascular technique that starts with nucleation of small
ice crystals in the extracellular fluid in tissue adjacent to the
balloon. Since ice does not incorporate solutes, a hypertonic
environment is created, leading to osmotic dehydration of
cells.9When theballoon is removed, the tissue thaws, isotonic
conditions are regained and smooth muscle cells rehydrate,9
inducing apoptosis. First short-term clinical studies of cry-
oplasty in femoropopliteal arterial disease appear favourable
compared with conventional angioplasty.10e13 In haemodial-
ysis accesses outcome after cryoplasty is still under
debate.14,15 So far, clinical studies have not provided enough
evidence for beneficial effects of cryoplasty in the reduction
nor the treatment of AV graft stenosis. The only cryotherapy
experimental animal in vivo study has been conducted in
rabbit iliac arteries after balloon angioplasty.16
In the present study, we tested the hypothesis that
primary cryoplasty at the venous anastomosis immediately
following surgery reduces IH in a porcine, bilateral, arte-
riovenous graft model.
Animals and methods
Graft implantation
In 12 female Landrace pigs weighing 52.3 0.8 kg expanded
polytetrafluoroethylene (ePTFE) grafts (W.L. Gore and
Associates, Flagstaff, AZ, USA) were inserted bilaterally
between the common carotid artery (CCA) and the internal
jugular vein as described previously.17e19 In each pig, one
graft was randomly assigned to undergo cryoplasty immedi-
ately after surgery. The contralateral graft served as control
and underwent conventional PTA treatment. The study
protocol was approved by the Institutional Review Board for
animal experimentation of the University Medical Center
Utrecht and conforms to the ‘Guidelines for the Care and Use
of Laboratory Animals’, published by the US National Insti-
tutes of Health (NIH Publication No. 85-23, revised 1996).
Anaesthesia
Before graft implantation and termination, the animals
were fasted overnight. On day 1, a fentanyl plaster
(25 mg h1) was applied to the skin. Animals were pre-
medicated with an intramuscular injection containing0.5 mg. After cannulation of an ear vein, an intravenous
injection of thiopental sodium 4 mg kg1 was administered.
Then, they were intubated and ventilated with a mixture of
O2 and air (1:2). During the operation, the ear vein was
used for continuous administration of 0.3 mg kg1 h1 mid-
azolam, 2.5 mg kg1 h1 sufentanil and 50 mg kg1 h1 pan-
curonium. The pigs were monitored by electrocardiogram
and capnography.
Oral anti-platelet therapy
Starting 6 days preoperatively, the pigs received acetylsa-
licylic acid 80 mg day1. Clopidogrel (Sanofi-aventis,
Gouda, the Netherlands) 225 mg was added 1 day preop-
eratively and continued at a dose of 75 mg day1 until
termination. Before graft puncturing for cryoplasty and
conventional angioplasty, an intravenous bolus of 10 mg
abciximab was administered.18
Antibiotics
Before operation, the animals received intravenous amox-
icilline/clavulanic acid 500/125 mg. Oral amoxicilline/
clavulanic acid 600/157.5 mg was administered on day 1
postoperatively.
Operative procedure
Operational procedure was performed as described
earlier.17 In short, through a longitudinal incision in the
midline of the neck, the CCA and the internal jugular vein
were dissected bilaterally. Baseline flow through the CCA
was measured using a 4-mm perivascular flow probe
(Transonic Systems, Maastricht, the Netherlands). Intrave-
nous heparin 100 IU kg1 was administered before vessel
manipulation.
Two vascular surgeons (G.J.d.B. and H.J.M.V.) created
the end-to-side anastomoses at a 45 angle using a contin-
uous 8/0 polypropylene suture. Sterile, reinforced, thin-
walled, ringed, ePTFE grafts (W.L. Gore & Associates,
Flagstaff, AZ, USA) were implanted (diameter 5 mm, length
7 cm). Then, blood flow through the artery and vein was
measured and graft flow was calculated as caudal CCA flow
minus cranial artery flow. After administration of abcix-
imab, each graft was punctured separately to perform the
interventional radiological procedure. After treatment, the
puncture hole was sutured using 6/0 polypropylene.
Cryoplasty
The PolarCath Peripheral Dilatation System (Boston
Scientific, Maastricht, the Netherlands) was used for cry-
oplasty. This system consists of a nitrous oxide-expanded
dual balloon catheter, a microprocessor-based inflation unit
and a nitrous oxide cylinder. A 6F sheath is placed in the
graft and the PolarCath balloon is advanced to the venous
anastomosis over a 0.035-inch guidewire. Upon entering the
balloon, the pressurised liquid nitrous oxide changes phase,
resulting in balloon expansion. The 4-mm diameter
balloon17 is inflated in 2-atmosphere (atm) increments until
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temperature on the surface of the balloon is reduced to
10 C. The treatment cycle lasts for 20 s, after which the
flow of nitrous oxide is automatically halted and the
balloon is passively warmed. After a fixed warming delay
(1 min), the balloon is then deflated and removed. The
contralateral site underwent conventional angioplasty
treatment (8 atm) using a 6F sheath and a 4-mm diameter
balloon.
Quantitative angiography
Angiograms of the venous runoff were obtained before
euthanasia (Philips, BV Pulsera, Eindhoven, the
Netherlands). Vessel diameters were measured on sub-
tracted digital images using a calibrated steel marker that
was carefully positioned parallel to the image intensifier
during imaging. Luminal diameters were measured
approximately 5-mm caudal to the toe of the venous
anastomosis. Quantitative angiographic analysis was per-
formed using ImageJ 1.41 software (National Institutes of
Health, USA).
Tissue preparation and morphometric analysis
After 4 weeks, pigs were anaesthetised as described
above. Heparin 100 IU kg1 was administered before
manipulation of the vessels. After determining graft flow
using the perivascular flow probe, angiograms of the AV
grafts were obtained via the femoral artery. Subsequently,
grafts and adjacent vessels were perfused with saline for
3 min followed by formalin at physiologic pressure
(100 mmHg). After 2 min, both sides of the arteries and
veins were then ligated, allowing pressure fixation of the
vessels. Subsequently, grafts and adjacent vessels were
excised and immersed in formalin for at least 24 h. The
fixated veins were cut in 5-mm blocks and embedded in
paraffin. Five-micrometres-thick sections were prepared of
the vein 1 cm caudal to the centre of the anastomosis, and
at the centre of the anastomosis. For morphometric
analysis, sections were stained with Elastica van Giesson
(EvG) for general morphology. Area measurements were
performed on captured images obtained with a colour
camera attached to a light microscope by using computer-
assisted morphometry. At the highest magnification that
allowed visualisation of the entire vein section in one field,
the intimal and medial areas and the area inside the
external elastic lamina (total vessel volume) were manu-
ally traced. The circumference of the vein was traced 1 cm
caudally to the centre of the anastomosis. To distinguish IH
from organised thrombi, sections were stained with hae-
matoxylin and eosin. Collagen was visualised using pic-
rosirius red staining and digital image microscopy with
circularly polarised light.
Immunohistochemical analysis: alpha-smooth
muscle actin
Following deparaffination and hydration, antigenic deter-
minants were unmasked (when necessary) by boiling in
10 mM citrate acid for 15 min. Next, the sections werepreincubated with 10% normal horse serum (Vector Labo-
ratories, Peterborough, UK) to block nonspecific binding.
Serial sections from each graft were then incubated with
mouse anti-a-smooth muscle actin at 1:1500 dilution
(Sigma, St. Louis, MO, USA). Subsequently, sections were
incubated with a biotinylated horse anti-IgG antibody
(Vector Laboratories, Peterborough, UK) for 1 h at room
temperature, followed by incubation with streptavidine
horseradish peroxidase (HRPO). For visualisation of the
HRPO, we used diaminobenzidine (DAB) in 0.05 M TriseCl
mixed with 0.01 M imidazole. Endogenous hydrogen perox-
idase was blocked by incubating the sections in 1.5%
hydrogen peroxide/methanol during deparaffination.
Statistical analysis
Data are presented as mean standard error of the mean.
Wilcoxon signed-rank test for paired data analysis was used
for comparison of graft blood flow, histomorphometry and
angiographic outflow vein diameters. Spearman’s rho was
used for correlation analysis of graft flow and intima/media
ratio. Analyses were carried out using SPSS 15.0 for
Windows (SPSS Inc., Chicago, IL, USA). A P-value <0.05
was considered statistically significant.
Results
Twenty-four ePTFE grafts were successfully implanted in 12
pigs. One pig died several hours postoperatively of unknown
aetiology. Of notice, post-mortem dissection showed intact
and patent anastomoses, foamy content in the trachea but
no malformations or thrombosis in heart or lungs. One pig
had bilaterally occluded grafts and in two pigs unilateral
graft occlusion occurred at the control side. Therefore, 16
grafts remained for further paired data analysis. These
grafts and outflow veins remained intact and no bleeding
complications occurred during follow-up. Angioplasty
procedures went uneventful.
Baseline carotid artery blood flows in the cryoplasty group
and the control group were 287 22 mlmin1 and
221 30 mlmin1, respectively (PZ 0.07). Graft blood flow
immediately after implantation was 767 151 ml min1 in
the cryoplasty group and 635 107 mlmin1 in the control
group (PZ 0.07). At 28 days, graft blood flow was
831 147 ml min1 in the cryoplasty group, and
902 102 ml min1 in the control group (PZ 0.33).
General histology
No obvious morphological differences were observed
between venous anastomosis sections of the cryoplasty
group and the control group. At 4 weeks, IH at the venous
anastomosis consisted of vascular smooth muscle cells,
extracellular matrix, fibroblasts, inflammatory cells,
macrophages and little collagen. Representative sections of
the venous anastomosis are shown in Fig. 1.
External parts of the grafts were lined with ‘foreign
body’ giant cells and macrophages. Inflammatory reactions
seen around the venous anastomosis were pig dependent,
not treatment dependent. Consistent thin vein media layers
were surrounded by adventitia with neovascularisation.
Figure 1 Representative Elastica van Giesson stained sections of the graft vein anastomosis of control animals (A: upper left panel)
and cryoplasty treated animals (B: upper right panel) (12.5magnification). Detail of a-SMA stained intimal hyperplasia in the control
group (C: middle left panel) and the cryoplasty group (D: middle right panel) (100 magnification). Note the extensive brown
coloration in both sections. Picrosirius-stained section of the venous anastomosis, visualised with polarised light in the control group
(E: lower left panel), and the cryoplasty group (F: lower right panel) (40 magnification).
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Data frommorphometrical analysis are presented in Table 1.
At 28 days, treatment with cryoplasty resulted in a 47%
reduction of intimal area at the venous anastomosis
(PZ 0.21) compared with the control group. Media thickness
did not differ between the two groups (PZ 0.78). Compared
with the control group, the intima/media (I/M) ratio was 45%
reduced in the cryoplasty group (PZ 0.07) (Fig. 2). The
caudal outflowvein vessel volume in the cryoplasty groupwas
not statistically different from the control group (PZ 0.87).
Interestingly, more significant I/M ratio reductions were
observed in those pigs that tended to develop more IH
(Fig. 2). The I/M ratio had no relation with graft flow at 4
weeks; Spearman’s rhoZ0.455 (PZ 0.26) in the control
group and rhoZ 0.214 (PZ 0.61) in the cryoplasty group.Angiographic luminal diameters of the caudal outflow
vein were 3.6 0.58 mm versus 3.8 0.48 mm in the cry-
oplasty group and control group, respectively (PZ 0.50).Discussion
In this validated, porcine AV graft study, preventive cry-
oplasty of the venous anastomosis was investigated for the
first time. A single cryoplasty treatment resulted in a non-
significant I/M ratio reduction after 4 weeks follow-up.
Interestingly, intima inhibiting effects may be most
profound in those subjects that tend to develop most IH.
Angiographic outflow vein diameter, graft blood flow and
histological outflow vein vessel volume were not different
between the two groups.
Figure 2 Individual intima/media (I/M) ratios at the centre
of the venous anastomosis in 8 pigs (lines represent paired
measurements in a single pig; each pig is represented by one
single symbol, e.g. an open square). Note the more significant
I/M ratio reduction in those pigs that tend to develop more
intimal hyperplasia in the control group *.
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Novel treatments have been developed to prevent the
formation of IH at the venous anastomosis of AV grafts.
Matrix metalloproteinase (MMP) inhibition has resulted in IH
reduction in a porcine, bilateral, carotid AV graft model.20
In the same model, the role of over-expression of C-type
natriuretic peptide and cell seeding with anti-CD34 anti-
bodies have been investigated without reducing intima
formation.19,21 Antiproliferative drugs such as paclitaxel,
but not dipyridamole, significantly reduced IH at the venous
anastomosis, both by perivascular delivery and by pacli-
taxel-coated grafts.22,23 In addition, drug-eluting balloons
have shown interesting results in animal coronary and
carotid arteries,24 and recently also in clinical peripheral
artery occlusive disease.25 Most promising results have been
reported using sirolimus-eluting stents in porcine AV
grafts,18 but vascular access graft stenting in clinical
practice is still controversial due to a lack of stenting
studies.26
Clinical studies in this field aim at secondary prevention
of IH. In a pilot study, endovascular brachytherapy
improved post-intervention primary patency but not 6-
month secondary patency.27 The use of a peripheral cutting
balloon for stenotic or thrombosed grafts did not improve
primary patency either.28 In a case report, cryoplasty
increased the intervention-free interval of five haemodial-
ysis grafts with rapidly recurring stenosis from 3 weeks to 16Table 1 Results of Elastica van Giesson stained morphometric
caudal in the outflow vein. Intima, media and vessel volume valu
range) was 1.11 (0.77e1.42) and 1.52 (1.21e2.31) for cryoplasty
Cryoplasty
Anastomosis Intima 1.93 0.48
Media 1.95 0.47
I/M 1.07 0.14
Outflow vein volume 18.49 6.67weeks,14 but Gray et al. found low anatomical success rates
after cryoplasty of dialysis accesses in a pilot study.15 Thus
far, no randomised controlled trials have been conducted
that have tested the efficacy of the PolarCath Peripheral
Dilatation System in AV accesses. Treatment of femo-
ropopliteal arterial disease has been investigated more
extensively,10e13 but no controlled clinical trials have been
conducted in this field either. Short-term results suggest
beneficial effects of cryoplasty in femoral artery stenoses,
but recent reports criticise the evidence and long-term
value.29,30
The pathogenesis of IH at the venous anastomosis is not
fully understood. It is also unclear why some patients are
especially at risk, whereas others are less likely to develop
IH. Interestingly, Fig. 2 suggests that cryoplasty might show
effect in pigs, which tend to develop relatively more IH
than others. Therefore, a selected group of haemodialysis
patients may benefit from preventive cryoplasty in the
clinical situation. However, treatment based on patient
selection requires more research.Cryoplasty rationale
Cryoplasty is an endovascular technique for treatment of
stenosis. Effects of cold therapy include a reduced elastic
recoil, apoptosis of smooth muscle cells,31e33 and, in
atherosclerotic arteries, an altered plaque response. A
single treatment cycle with the PolarCath Peripheral
Dilatation System lasts for 20 s. In haemodialysis grafts,
residual stenosis has been negatively correlated with the
duration of the inflation,34 so additional treatments may be
required in case of resistant stenosis. Whereas angioplasty
itself results in an early apoptotic response,35 and vein wall
thickness is much thinner compared with arteries, loss of
vein wall integrity may possibly result in a higher incidence
of complications such as dissection or perforation. Such
complications were not seen in our study.
Ten weeks after applying an average wall temperature
of 26 C in a balloon injury rabbit iliac artery model, IH
had increased twofold in cryotherapy-treated arteries, and
collagen content had increased in all vessel wall layers.16
However, more recent studies found that the optimal
temperature for smooth muscle cell apoptosis is thought to
be approximately 10 C.32,33 In our study, 10 C was used
for cryoplasty. Angiographic diameter of the caudal outflow
vein, graft flow measurements and picrosirius-stained
sections did not significantly vary between the control
group and the cryoplasty group. Venous widening is
a pivotal feature of native vascular access maturation. Inanalysis of the centre of the venous anastomosis and 1 cm
es are expressed as mm2 SE. Median I/M ratio (interquartile
and control group, respectively (PZ 0.07).
Control Difference P
3.62 0.18 47% 0.21
2.10 0.74 7% 0.78
1.94 0.41 45% 0.07
17.08 2.49 8% 0.87
Cryoplasty for Intimal Hyperplasia Prevention 625our study, angiographic diameters and outflow vein volume
showed limited venous widening just caudal of the toe of
the anastomosis (Table 1). However, these results were
consistent in both groups.
Limitations
The P-value (0.07) of I/M ratio difference between cry-
oplasty and control group (Table 1) may suggest an insuf-
ficient number of operated pigs. However, sample size
calculation for this study was based on 50% I/M reduction by
cryoplasty and required eight animals for paired analysis.
Furthermore, a possible I/M ratio outlier is observed in the
control group (Fig. 2). A lower I/M ratio in that particular
control animal would have resulted in a smaller I/M
difference between cryoplasty and control group, but due
to paired analysis such a reduction most likely would not
have affected the P-value.
Our porcine AV graft model was developed for a follow-
up duration of 4 weeks and showed AV graft failure due to
thrombosis at longer follow-up.17 In a balloon-injured
rabbit iliac artery model, IH increase was observed at 10
weeks after cryotherapy at 26 C.16 However, treatment
temperatures were much colder and arteries were treated
instead of veins. Midterm histology at the venous anasto-
mosis is potentially interesting and requires prolonged
follow-up time in a new model.
We used 4-mm balloons for the angioplasty procedures.
Since porcine jugular veins are approximately 4-mm in
diameter,17 mechanical stress due to overstretch of the
anastomosis was limited. The observed results should
therefore be imputed to effects of cold treatment rather
than to PTA.
Our porcine model has previously shown to result in
rapid thrombosis formation when the AV graft is punctured
for treatment purposes.18 Although extensive anticoagulant
therapy was used perioperatively, three pigs had throm-
bosed grafts. The angioplasty procedure itself may have
been an extra thrombogenic factor by causing increased
endothelial damage. However, a clear explanation for our
thrombosis rate cannot be found.
Finally, cardiovascular risk factors and the uraemic
milieu were not present in this model. Any effects on
vascular remodelling and IH were not included. Therefore,
extrapolation to the human situation should be exerted
with caution.
Conclusion
Our results suggest that preventative cryoplasty of the
venous anastomosis of porcine AV grafts might help to
prevent the development of IH in those subjects who tend
to develop most profound IH. Given our results, preventive
cryoplasty may warrant further investigation.
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